SEK 0.65
(-3.25%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | -1.09 Million SEK | 0.0% |
2022 | - SEK | 0.0% |
2021 | - SEK | 0.0% |
2020 | - SEK | 0.0% |
2019 | - SEK | 0.0% |
2018 | - SEK | 0.0% |
2017 | - SEK | 0.0% |
2016 | - SEK | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | 113 Thousand SEK | 0.0% |
2024 Q1 | - SEK | 0.0% |
2023 Q3 | - SEK | 0.0% |
2023 Q4 | - SEK | 0.0% |
2023 FY | - SEK | 0.0% |
2023 Q2 | - SEK | 0.0% |
2023 Q1 | - SEK | 0.0% |
2022 Q3 | - SEK | 0.0% |
2022 Q4 | - SEK | 0.0% |
2022 Q2 | - SEK | 0.0% |
2022 Q1 | - SEK | 0.0% |
2021 Q4 | - SEK | 0.0% |
2021 Q3 | - SEK | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
AlzeCure Pharma AB (publ) | -2508.00 SEK | -43719.777% |
BioGaia AB (publ) | 181.2 Million SEK | 100.606% |
Enzymatica AB (publ) | 11.49 Million SEK | 109.557% |
Enorama Pharma AB (publ) | 4.29 Million SEK | 125.606% |
Gabather AB (publ) | -1772.00 SEK | -61920.316% |
Klaria Pharma Holding AB (publ.) | - SEK | Infinity% |
Moberg Pharma AB (publ) | 7.11 Million SEK | 115.446% |
Nanexa AB (publ) | 1.91 Million SEK | 157.509% |
Newbury Pharmaceuticals AB (publ) | 4.99 Million SEK | 122.002% |
ODI Pharma AB | - SEK | Infinity% |
Orexo AB (publ) | 42.4 Million SEK | 102.592% |
Probi AB (publ) | 116.7 Million SEK | 100.942% |
Swedencare AB (publ) | 398.1 Million SEK | 100.276% |
Swedish Orphan Biovitrum AB (publ) | 3.87 Billion SEK | 100.028% |
Toleranzia AB | -1.34 Million SEK | 17.985% |
Vivesto AB | - SEK | Infinity% |